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Background. The potential delays caused by transport of blood cultures to server laboratories might result in delayed issuance of results for patients with positive blood cultures. In this study, we aimed to determine the clinical impacts of inter-site transport of blood cultures.
Methods. We performed a retrospective cohort study involving cases with positive blood cultures (1 positive blood culture/species/patient/7 days; not deemed as a contaminant) at two sites of a Canadian tertiary care center between January 1, 2018 and December 31, 2018. Blood cultures from the affiliated site were transported to the laboratory of the primary server site. These two sites are located 8 km apart. The following outcomes were studied: the duration between blood culture sampling and issuance of the first report and the duration between blood culture sampling and administration of the first effective antibiotic.
Results. We observed 349 episodes of bacteremia, including 161 in the affiliated site (45.5%) and 193 in the primary server center (54.5%). Enterobacteriaceae (n = 151, 43%) and Staphylococcus aureus (n = 77, 22%) were the most commonly observed causative bacteria. Median duration for issuance of the first positive report was significantly shorter in the primary server hospital (32.4 h, interquartile range [IQR] 19.8-44.3) than in the affiliated center (37.9 h, IQR 24.1-46.5; P = 0.004). The median duration between blood culture sampling and administration of the first effective antibiotic was 2.7 h in the server site (IQR 0.75-15.2) and 2.3 h in the affiliated site (IQR 1-8.45) (P = 1.0). Receiving the first effective antibiotic after blood culture sampling required > 60 min in 8/189 patients (4.2%) in the affiliated site and 9/158 patients (5.7%) in the primary server site (P = 0.3). The 30-day mortality was 13.8% (26/189) and 8.9% (14/158) at the primary server site and affiliated site, respectively (P = 0.16).
Conclusion. Inter-site transport of blood cultures is associated with a significant delay in the issuance of positive blood culture reports. However, this delay does not cause any delay in administration of effective antibiotic therapy because of rapid recognition of sepsis in bacteremia patients. These results are reassuring in the context of increasing microbiology service centralization.
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No reported disclosures. Saturday, October 5, 2019: 12:15 PM Background. Susceptibility-guided treatment of H. pylori is superior to empiric therapy. We determined the accuracy of whole-genome sequencing (WGS) compared with phenotypic testing using CLSI/EUCAST breakpoints.
Activity of Fosfomycin (FOF) and Frequency of Nonsusceptible Inner Colonies During Susceptibility Testing of an International Collection of Clinical
Methods. Thirty-three clinical isolates of H. pylori cultured from gastric biopsies were sequenced with a coverage range between 40x and 80x using Illumina Miseq platform and the reads were assembled and annotated with PATRIC. Phenotypic susceptibility tests were performed using E-test strips under microaerophilic conditions for 72 hours. Mutations associated with amoxicillin, tetracycline, clarithromycin, levofloxacin, metronidazole and rifampin resistance were examined.
Results. Of the 33 isolates, two were phenotypically resistant to amoxicillin: one carried a β-lactamase gene (bla ) and the other exhibited a point mutation pbp2 (A541T). All isolates were tetracycline susceptible phenotypically, but three isolates had point mutations in 16S rRNA that are associated with resistance (A926G). Clarithromycin results showed a good correlation between methods. Nine clarithromycin-resistant isolates demonstrated point mutations in 23S rRNA (A2142G/ A2143G). Fifteen isolates were phenotypically resistant to levofloxacin, but resistance mutations were found in only 14 strains (N87I/N87K/D91Y/D91N/D91G/D99N in gyrA). We analyzed our strains for the presence of intact genes rdxA and frxA, either of which convert the prodrug form of metronidazole into the active form. Twenty-four
